Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference
Larimar Therapeutics (Nasdaq: LRMR) announced that CEO Carole Ben-Maimon will present at the JMP Securities Life Sciences Conference on June 16-17, 2021. The presentation will take the form of a fireside chat scheduled for 2:00 PM ET on June 16. Larimar focuses on developing treatments for rare diseases, currently evaluating its lead compound, CTI-1601, in a Phase 1 clinical program for Friedreich’s ataxia. The company aims to utilize its platform for creating fusion proteins targeting additional rare diseases.
- None.
- None.
BALA CYNWYD, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in virtual 1x1 investor meetings at the JMP Securities Life Sciences Conference taking place from June 16-17, 2021. See below for more details.
| Presentation Format: | Fireside chat |
| Date: | June 16, 2021 |
| Time: | 2:00 PM ET |
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich’s ataxia (FA). Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
What is Larimar Therapeutics presenting at the JMP Securities Life Sciences Conference?
When is the Larimar presentation scheduled?
What is the main focus of Larimar Therapeutics?
What is the lead compound of Larimar Therapeutics?
What is the stock symbol for Larimar Therapeutics?
